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- 
A total of 47 nonimmune febrile patients from Pikine, Senegal, with >IO00 Plasmodium falcipari~t~~ 
asexual forms per pl whole blood were given 12.5 mg per kg body weight of mefloquine in a single or;ll 
dose and were followed up daily until day 7 and also on day 14 of the study. 
Seven of the patients who vomited, four who had 4-aminoquinolines in their blood, and five drop 
outs were excluded. Fever and parasitaemia were suppressed within four days until day fourteen in ;-I!! 
of the 31 remaining patients, including 10 with P. falciparum strains that had a low sensitivity to meflo 
quine. Two failures were due to poor absorption of mefloquine. The presence of P. falciparum strairt:; 
with low in vitro susceptibility to mefloquine did not affect, within 14 days, the clinical and parasitologicitl 
efficacy of a single oral dose mefloquine regimen in patients who had received no previous antimalari;tl 
treatment and who did not have partial immune protection. 
Introduction 
Chloroquine-resistant falciparum malaria has spread 
all over West Africa, one of the last countries to 
be affected being Senegal ( I ) .  Mefloquine is now 
available in several West African countries, and 
the recommended oral therapy is a single dose of 
12.5-15 mg per kg body weight (2). Recent in vitro 
studies have reported the presence of Plasmodium 
falciparum strains with reduced susceptibility to 
mefloquine in West Africa (3), in particular in Mali 
and Senegal (4) ,  and, several mefloquine prophylaxis 
failures in vivo were observed in 1988 in travellers 
returning from West Africa (5). The present study 
was undertaken to determine the in vitro and in vivo 
effectiveness of mefloquine against P. fakiparum 
strains in Senegal and to assess the in vitro sensitivi- 
ty of these strains to chloroquine and halofantrine. 
Materials and methods 
Selection. of patients. A total of 47 patients from 
Pikine, a suburb of Dakar, were enrolled in the 
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study. The patients were selected from those wlii ' 
presented voluntarily in November 1988 at O U I  
patients clinics with fever or a history of few1 
during the previous 48 hours, without neuro1ogic:l I 
signs. Only patients older than 1 year with P.  fak f  
parum parasite densities 21000 asexual forms per 11 I
of blood were included. The free and informctl 
consent of the subjects or one of their parents W;I!I 
obtained. 
Drug dosages. The Dill-Glazko urine test (6) ant1 
the day-O level of total blood 4~aminoquinolinc~; 
(obtained using high-performance liquid chromatog 
raphy (HPLC)) (7) were determined for 38 patients 
The day-2 total venous blood levels of mefloquinc' 
and of 4-carboxymefloquine (the major metabolitc I 
were determined by HPLC (8) in 37 patients. 
In vivo test. The patients received 50 mg or 250 rng 
tablets of mefloquine,a corresponding to a totnJ 
amount of 12.5 mg per kg in a single oral dose. Thc 
patients were observed for 1 hour after receiving thc 
drug to monitor possible secondary effects or vomi- 
ting; patients who vomited were excluded from thc 
study. The WHO 14-day extended test was success- 
fully completed by 31 patients. A thick blood film 
was prepared and the temperature of the patients was 
recorded daily on days 0-7, and again on day 14. 
After staining with Giemsa, the number of asexual 
parasites per 1000 white blood cells was counted and 
the parasite density per pl calculated, assuming il 
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mean of 8000 leukocytes per pl of blood. The 
patients in whom asexual forms persisted until day 7 
were routinely treated with a standard oral regimen 
of chloroquine (25 mg per kg) over 3 days. Suscepti- 
bility was defined according to WHO criteria (9). 
In vitro test. Samples of 5 ml of venous blood were 
collected at enrolment in anticoagulant acid citrate 
dextrose solution, stored at + 4 OC, and sent tlo Paris. 
The in vitro sensitivity of the P. fakiparum strains 
to chloroquine, mefloquine, and halofantrine was 
evaluated with the semimicro test, using [3H]-hypo- 
xanthine to assess parasite growth (10). Twofold 
dilutions of the following drugs were used: chloro- 
quine (12.5-1600 nmol.l-'), mefloquine, (2.5 - 400 
nmol.l-'), and halofantrine (0.25-32 nmol.1-I). Each 
assay was performed in triplicate. Within 5 days of 
sampling, the red blood cells were washed, introdu- 
ced at 2.5% haematocrit to 0.7-ml wells containing a 
mixture of RPMI 1640 supplemented with 10% (v/v) 
normal human serum and various drug doses, and 
incubated for 42 hours at 37 "C in a gaseous mixture 
consisting of 5% (v/v) oxygen, 5% (v/v) carbon 
dioxide, and 90% (v/v) nitrogen.b A total of 1 pCi 
[3H]-hypoxanthine was added to each well after 18 
hours. Parasites were harvested on filters after 42 
hours and isotopic incorporation was evaluated using 
a scintillation spectrophotometer. Parasite median 
inhibitory concentrations (I(&) of 2 100 nmol.1-' of 
chloroquine, of 240 nmol.1-' of mefloquine, or of 
230 nmol.1-' of halofantrine were taken to indicate 
resistance to chloroquine or low sensitivity to meflo- 
quine or halofantrine. 
Results 
4-Aminoquinoline and Dill-Glazko urine tests were 
performed on 38 of the 47 patients recruited for the 
study, 42 completed the in vitro test, the level of 
mefloquine was determined in 37 (age range, 1-40 
years), and 35 were followed up until day 14 of the 
study. 
Previous 4-aminoquinoline intake. A total of 19 
subjects had detectable 4-aminoquinoline in their 
blood (by HPLC). Levels of chloroquine plus des- 
ethylchloroquine of 17-140 nmol.1-' were found in 
14 patients, four had levels of 473-1948 nmol.l-', 
and one patient had 5228 nmol.1-' of monodesethyla- 
modiaquine in total blood. No correlation was found 
between the results of the HPLC and Dill-Glazko 
urine tests. Of 15 subjects with a positive urine test, 
Heraus incubator, Hanau, Germany. 
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11 had a negative blood test. Also of 18 subjects 
with a positive urine test, 10 had detectable levels of 
4-aminoquinoline in their blood. 
In vivo tests. Seven of the nine patients who vomited 
on day O were withdrawn from the study on day 1 
(including the patient who had monodesethylamodia- 
quine in his blood) and were given alternative treat- 
ment; five did not complete the test; and another four 
were omitted from the analysis because their total 
blood chloroquine plus desethylchloroquine was 
more than 150 nmol.1-l on day O. A total of 31 tests 
were successful: parasitaemia and fever cleared in 29 
patients within 4 days (Fig. 1); two patients who had 
an RI1 and an RI11 response were discharged on day 
14 and day 5, respectively, and then cured with a 
25 mg per kg oral regimen of chloroquine (Table 1). 
Blood mefloquine levels. The average mefloquine 
blood levels on day 2 were not different for the nine 
patients who reported that they had vomited 1-6 
hours after swallowing the drug and for the 28 
patients who did not report having vomited. For 29 
subjects who had no recrudescence, the total blood 
mefloquine and 4-carboxymefloquine levels 48 hours 
after drug intake were 362-17 19 ng.ml-' (average, 
955 k 74 ng.ml-') and 50-1 180 ng.ml-' (average, 
407 k 49 ng.ml-'), respectively, without significant 
variation with age oc sex. For the RI11 and RI1 cases, 
respectively, the total blood levels of mefloquine 
were 150 ng.ml-' and 180 ng.mI-' and of 4-carboxy- 
mefloquine, 140 ng.ml-' and 243 ng.ml-l. 
Fig. 1 .  Plot of the geometric mean parasite density 
(GMPD) expressed a s  the number of asexual forms per 
p.1 of blood (based on 8000 white blood cells per p.1 of 
blood) and the mean patient temperature during the 
study. 
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Table 1 : Data on the two mefloquine treatment failures 
Case 1 C a s e  2 
Age 
No. of parasites 
per pl: 
Day O 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 14 
Levels of mefloquine 
in blood (ng.mV) 
Day 2 
Day 5 
Parasite strain 
Chloroquine 
Mefloquine 
IC,, (nmo1.l-1) 
20 months 3.5 years  
64 O00 (38.9) a 
5600 (37.2) 
800 (36) 
400 (37) 
- 
30 (36) , 
10 (36.4) 
160 (37.1) 
180 
- 
27 200 (38.5) 
240 O00 (37.2) 
24 O00 (37.5) 
20 O00 (40.7) 
168 O00 (37.9) 
200 O00 (37.5) 
150 ' 
124 
48 
32 
~ 
a Figures in parentheses  a r e  the  patient's temperature in "C. 
In vitro tests. A total of 42 itz viti-o tests were per- 
formed; of these, 7 (19%) gave an invalid result 
(insufficient sample or bacterial contamination), 
while 35, 33, and 34, respectively, gave an accep- 
table result for chloroquine, mefloquine, and halo- 
fantrine susceptibility tests. Thirty-three strains of 
P.  fulcipul-um (94%) were sensitive to chloroquine 
and two (6%) were resistant, the sensitive strains 
being inhibited at a mean IC,, of 24.2 nm01.l-~. 
Twenty-three strains (70%) were sensitive to meflo- 
quine, while 10 (30%) had low sensitivity, the sensi- 
tive strains being inhibited at a mean IC,, of 
20.6 nmol.1-I (for mefloquine, 1 ng.ml-' = 2.17 
nmol.1-I). Twenty-three strains (68%) were sensitive 
to halofantrine and 11 (32%) had low sensitivity, the 
sensitive strains being inhibited at a mean IC,, of 
16.6 nmo1.P' (Fig. 2). 
Of the 10 patients with low sensitivity in vitro to 
mefloquine, seven completed the in vivo test. The 
strains involved were suppressed without recrudes- 
cence on day 14 by the mefloquine regimen. There 
was no significant correlation between the response 
to mefloquine and chloroquine (I- = 0.04; degrees of 
freedom = 32) or between that to halofantrine and 
chloroquine ( r  = 0.06; degrees of freedom = 33). 
Correlation between the IC,, for mefloquine and 
halofantrine was highly significant (r = 0.8 1; degrees 
of freedom = 32). 
Discussion 
Mefloquine has been available since 1984 for the pro- 
phylactic treatment of visitors to Africa but has not 
yet been used by Senegal residents. Prophylactic fail- 
ures of mefloquine were first demonstrated in West 
Africa a few months before the present study (5). 
Pikine was chosen for the study since the sea- 
sonal transmission of malaria is low and malarial 
patients supposedly do not have partial immunity. Of 
Fig. 2. Plots showing the range of IC,, values in the in vitro tests for 35 Plasmodium fakiparum isolates for chloro- 
quine, mefloquine, and halofantrine. S t r a i n s  above the cut-off value were resistant (chloroquine) or less sensitive (meflo- 
quine and halofantrine). 
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the subjects, 34 stated that they had not left Pikine in 
the 2 months prior to the study. On the basis of the 
results of interviews or of the urine Dill-Glazko 
tests, previous antimalarial intake by the participants 
could not be ruled out. The successful in vitro grow- 
th of parasites from three subjects who stated that 
they had received an intramuscular injection of qui- 
nine between one day and seven days before the 
study demonstrates the lack of efficacy of this pre- 
vious treatment, which was probably inadequate. 
For all patients with mefloquine blood levels of 
2 362mg.ml-I on day 2, parasitaemia and fever 
cleared within 96 hours without recrudescence until 
day 14. These blood levels are approximately two- 
thirds of the mean, day-2 wholle blood mefloquine 
concentration that has been reported for Thai 
malarial patients receiving 15 mgkg-' of mefloquine 
( I l ,  12). 
Oduola et al. have proposed an in vitro cut-off 
point for resistance to mefloquine of IC,, = 
26 nmol.1-' (12 ng.ml-'). The median IC,, for Afri- 
can P.  falciparum strains that we studied in 1983-89 
was 12.3 k 13.6nmol.l-' (n = 762) for mefloquine 
and 7.5 k 10.4 nmol.1-I (n  = 349) for halofantrine 
(normal distribution). In the absence of a series of in 
vitro tests of mefloquine treatment failures, those 
strains with mefloquine IC,,s 2 40 nmol.1-I (mean 
IC,, + 2SD) may be considered to have low sensiti- 
vity. In our study, 10 strains of P.  falcipamm with 
mefloquine IC,,s of 45-1 10 nnnol.l-' were cleared 
before day 14 by a single 12.5 mg per kg oral dose 
of mefloquine. The lowest sensitivity strains were 
isolated from two children (aged 2 years and 4 years) 
who cannot be considered to be semi-immune. These 
children had no detectable 4-aminoquinoline in 
samples of blood on day O, an adequate mefloquine 
level on day 2 (684 ng.ml-' and 745 ng.ml-'), and 
were successfully cured. 
The treatment failures were probably due to 
poor absorption of mefloquine (the RI11 patient, who 
had a P.  falciparum strain with a mefloquine IC,, of 
32 nmol.1-I) and to poor absorption and/or low 
mefloquine sensitivity of the strain involved (the RI1 
patient, who failed the in vitro test). These two chil- 
dren did not vomit after taking the mefloquine. We 
were not able to observe late treatment failures since 
the fallow-up period lasted only 14 days. 
Strains of P.  fakiparum that have low sensitivi- 
ty to mefloquine occur in areas where the drug has 
never been used and where most P. fakiparum 
strains are still sensitive to chloroquine. Neverthe- 
less, this low sensitivity to mefloquine still permits 
the standard mefloquine regimen to be effective. The 
highly significant correlation between the in vitro 
response of the P. fakiparum strains to mefloquine 
and halofantrine limits the perspective of halofan- 
366 
trine as a replacement drug if mefloquine-resistant 
P. falcipariim malaria emerges in West Africa. 
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Résumé 
Sensibilité des souches de Plasmodium 
falciparum à la mefloquine dans une zone 
urbaine du Sénégal 
Afin d'évaluer l'efficacité curative de la méfloqui- 
ne dans le paludisme à f. falciparum dans un 
pays d'Afrique de l'Ouest où des souches faible- 
ment sensibles in vitro et des échecs prophylac- 
tiques à la méfloquine avaient été observés en 
1987-1988, nous avons effectue une étude in 
vivo en novembre i988 au Sénégal. Quarante- 
sept sujets fébriles se présentant aux dispen- 
saires de Pikine, un faubourg de Dakar à trans- 
mission saisonnière faible, avec une parasitémie 
isolée suipérieure à 1000 trolphozoi'tes de f. falci- 
parumlyl ont reçu une dose orale unique de 12'5 
mg/kg de méfloquine et ont été suivis quotidien- 
nement jusqu'au 7ème jour et au 14ème jour. 
Sept sujets qui ont présenté des vomissements et 
5 sujets qui ne sont pas revenus ont été exclus. 
Quatre patients présentaient une concentration 
d'amino-4-quinoléines dans le sang total supé- 
rieure a i50 nmol/l et ont également éte exclus. 
La parasitémie et la fièvre ont disparu avant le 
4eme jour chez 29 malades. U n  échec RI1 et un 
échec RlIl ont été observés. Quarante-huit 
heures après traitement, la méfloquinémie était 
de 955 -C 74 ng/ml dans 29 succès et 150 et 180 
ng/ml dans 2 échecs. La culture in vitro a mis en 
évidence une faible sensibilité à la méfloquine de 
I O souches sur 33 = 45 à 110 nmol/l), une 
résistance à la chloroquine pour 2 souches sur 
35 (CI5,, = 300 et 500 nmol/l) et une faible sensi- 
bilité à I'halofantrine ~ 3 2  nmol/l) pour I I  
isolements de P. fakiparum sur 34. Les concen- 
trations médianes inhibitrices d'halofantrine 
et de méfloquine pour 33 isolements de 
P. fakiparum étaient fortement corrélées. Les 2 
échecs étaient dus à un taux sanguin insuffisant 
de méfloquine et/ou à la faible sensibilité des 
souches plasmodiales. Des souches de 
P. fakiparum faiblement sensibles à la méfloqui- 
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ne sont présentes dans cette région d’Afrique 
alors que ce médicament n’y est pas utilisé et 
que la plupart des souches restent sensibles à la 
chloroquine. Malgré cette faible sensibilité des 
parasites à la méfloquine, l’efficacité thérapeu- 
tique à dose unique de cette molécule est satis- 
faisante chez des sujets dépourvus d’immunité 
protectrice. 
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